Metrion Biosciences appoints Dr Chris Mathes as Chief Commercial Officer

FHS
July 24, 2024
10:31 am

Metrion Biosciences Ltd (“Metrion”), the specialist preclinical contract research organization (CRO) and a leader in ion channel screening, today announced the appointment of Dr Chris Mathes, MBA, as Chief Commercial Officer (CCO). Chris will work alongside the Company’s expert leadership team to drive commercial strategy and lead global business development and marketing activities.

Another Win for Antibody-Drug Conjugate in HER2+ Breast Cancer With Brain Mets

Trastuzumab deruxtecan (Enhertu, T-DXd) therapy produced “substantial and durable” overall and intracranial clinical activity in patients with HER2-positive advanced breast cancer, according to data from

September 15, 2024

Screen time and autism, TikTok and birth control, fighting disinformation

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Election Day is finally here. What to

November 5, 2024

Novo’s oral amycretin could lead to more weight loss beyond 12 weeks, according to early-stage trial

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

September 12, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.